(800) 943-6396

150 Essex St, Millburn, NJ 07041, USA

©2020 by Bon Opus Biosciences, LLC.

HDAC1 Recombinant Rabbit monoclonal Antibody IgG

SKU: BA111416-100µl
$279.00Price

Fig1: Western blot analysis of HDAC1 on different lysates using anti-HDAC1 antibody at 1/1,000 dilution.

Positive control:   

Lane 1: Hela              

Lane 2: Jurkat 

Lane 3: K562

Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-HDAC1 antibody. Counter stained with hematoxylin.

Fig3: Immunohistochemical analysis of paraffin-embedded mouse colon tissue using anti-HDAC1 antibody. Counter stained with hematoxylin.

Bon Opus Cat. #BA111416
Size
  • Host Species; Species Reactivity

    Rabbit; Human, Mouse, Rat
  • Immunogen

    Recombinant protein
  • Application Summary

    WB, ICC/IF, IHC
  • Purification; Formulation

    ProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
  • ALTnames

    Histone deacetylase 1
  • Background

    Acetylation of the histone tail causes chromatin to adopt an "open" conformation, allowing increased accessibility of transcription factors to DNA. The identification of histone acetyltransferases (HATs) and their large multiprotein complexes has yielded important insights into how these enzymes regulate transcription. HAT complexes interact with sequence-specific activator proteins to target specific genes. In addition to histones, HATs can acetylate nonhistone proteins, suggesting multiple roles for these enzymes. In contrast, histone deacetylation promotes a "closed" chromatin conformation and typically leads to repression of gene activity. Mammalian histone deacetylases can be divided into three classes on the basis of their similarity to various yeast deacetylases. Class I proteins (HDACs 1, 2, 3, and 8) are related to the yeast Rpd3-like proteins, those in class II (HDACs 4, 5, 6, 7, 9, and 10) are related to yeast Hda1-like proteins, and class III proteins are related to the yeast protein Sir2. Inhibitors of HDAC activity are now being explored as potential therapeutic cancer agents.(ET1605-35)